Dong-A ST, Last Year's Sales 605.2 Billion KRW... Operating Profit Up 17%

Dong-A ST announced on the 14th through an earnings report that last year's sales amounted to 605.221 billion KRW, and operating profit was 35.766 billion KRW. Compared to 2022, sales decreased by 4.8%, while operating profit increased by 17.2%. The company explained that the sales decline was influenced by the diagnostic business sector, and excluding this, last year's sales were 586.2 billion KRW, a 3.2% increase compared to 2022.

Exterior view of Dong-A ST headquarters building
[Photo by Dong-A ST]

By segment, prescription drug sales grew by 11.3% year-on-year, driven by the growth of the human growth hormone Grotropin and the diabetes treatment drug Suganon. Overseas business recorded 139.4 billion KRW, down 10.7% from the previous year. Sales of anemia treatment Dabepeotin Alpha and anti-tuberculosis drugs Croserin and Clopazimin increased by 55.4% and 23.5%, respectively, but sales of Baksas decreased by 25.8% due to the economic downturn in Cambodia, a major export market for Baksas.

In terms of operating profit, despite R&D expenses increasing by 7.9% compared to 2022, the company succeeded in achieving 17% growth year-on-year through improved cost of sales ratio of prescription drugs driven by increased sales volume of Grotropin and efficiency in selling and administrative expenses.